Section Arrow
CRVS.NASDAQ
- Corvus Pharmaceuticals
Quotes are at least 15-min delayed:2026/07/25 10:21 EDT
Regular Hours
Last
 13.07
-0.61 (-4.46%)
Day High 
13.875 
Prev. Close
13.68 
1-M High
16.47 
Volume 
955.99K 
Bid
13.1
Ask
14.19
Day Low
13.04 
Open
13.75 
1-M Low
12.5 
Market Cap 
1.15B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 14.57 
20-SMA 14.74 
50-SMA 13.31 
52-W High 26.95 
52-W Low 3.96 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.55/-0.75
Enterprise Value
1.15B
Balance Sheet
Book Value Per Share
2.86
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OTLKOutlook Therapeutics1.405+0.085+6.44%-- 
CLDICalidi Biotherapeutics0.1-0.005-4.76%-- 
MTNBMatinas Biopharma Holdings Inc0.2414-0.0078-3.13%-- 
RXRXRecursion Pharmaceuticals2.96-0.05-1.66%-- 
SPROSpero Therapeutics1.19+0.03+2.59%4.3PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cellactivation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.